Background
Age-related chronic diseases including dementia, type II diabetes and cardiovascular disease are becoming more prevalent and of increasing societal concern. Common denominators of these co-morbidities are insulin-resistance and impaired vascular function. Insulin-resistance is also associated with cognitive decline, while impaired brain vascular function is an important event preceding the development of impaired cognitive performance. We have already shown in a 12-week trial beneficial effects of the protein hydrolysate (NWT-03) on cognitive performance. However, underlying mechanisms have not yet been addressed, while the longer-term effects remain unknown.

Objective
The primary objectives of this trial are to evaluate effects of NWT-03 on cerebral blood flow as quantified by magnetic resonance imaging perfusion method Arterial Spin Labeling, and cognitive performance using a neurophysiological test battery (CANTAB). Secondary study objectives are to examine effects on insulin-sensitivity and peripheral vascular function.

Methods
This intervention study will take place over 36-weeks and has a randomized, controlled, parallel design. Forty-four older adults (aged 60-75 years) deemed overweight or obese (BMI: 25-35 kg/m²) with subjective cognitive decline will consume 5.7 g of NWT-03 or placebo powders daily.

Valorization
The lack of effective treatments for dementia and other age-related chronic diseases marks a great need to prevent the onset. This study aims to increase our knowledge of the role that a protein hydrolysate can have on vascular function and brain health in people who are at risk for cognitive impairment, allowing for improvement by the intervention.

Funding
This study is part of a project conducted within the Health Holland framework, which is partly funded by Newtricious R&D.